Using Medical Claims Database to Develop a Population Disease Progression Model for Leuprorelin-Treated Subjects with Hormone-Sensitive Prostate Cancer by Zou, Yixuan et al.
UKnowledge 
University of Kentucky 
UKnowledge 
Pharmacy Practice and Science Faculty 
Publications Pharmacy Practice and Science 
3-24-2020 
Using Medical Claims Database to Develop a Population Disease 
Progression Model for Leuprorelin-Treated Subjects with 
Hormone-Sensitive Prostate Cancer 
Yixuan Zou 
University of Kentucky, yixuanzou@gmail.com 
Fei Tang 
University of Kentucky, fei.tang@uky.edu 
Jeffery C. Talbert 
University of Kentucky, jeff.talbert@uky.edu 
Chee M. Ng 
University of Kentucky, chee.ng@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/pps_facpub 
 Part of the Oncology Commons, Pharmacy and Pharmaceutical Sciences Commons, and the 
Statistics and Probability Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Zou, Yixuan; Tang, Fei; Talbert, Jeffery C.; and Ng, Chee M., "Using Medical Claims Database to Develop a 
Population Disease Progression Model for Leuprorelin-Treated Subjects with Hormone-Sensitive Prostate 
Cancer" (2020). Pharmacy Practice and Science Faculty Publications. 47. 
https://uknowledge.uky.edu/pps_facpub/47 
This Article is brought to you for free and open access by the Pharmacy Practice and Science at UKnowledge. It 
has been accepted for inclusion in Pharmacy Practice and Science Faculty Publications by an authorized 
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Using Medical Claims Database to Develop a Population Disease Progression Model for 
Leuprorelin-Treated Subjects with Hormone-Sensitive Prostate Cancer 
Notes/Citation Information 
Published in PLOS ONE, v. 15, no. 3, p. 1-22. 
© 2020 Zou et al. 
This is an open access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited. 
Digital Object Identifier (DOI) 
https://doi.org/10.1371/journal.pone.0230571 
This article is available at UKnowledge: https://uknowledge.uky.edu/pps_facpub/47 
RESEARCH ARTICLE
Using medical claims database to develop a
population disease progression model for
leuprorelin-treated subjects with hormone-
sensitive prostate cancer
Yixuan Zou1,2, Fei TangID1, Jeffery C. Talbert3, Chee M. Ng1,4*
1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY,
United States of America, 2 Department of Statistics, University of Kentucky, Lexington, KY, United States of
America, 3 Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky,
Lexington, KY, United States of America, 4 NewGround Pharmaceutical Consulting LLC, Foster City, CA,
United States of America
* cheemng@gmail.com
Abstract
Androgen deprivation therapy (ADT) is a widely used treatment for patients with hormone-
sensitive prostate cancer (PCa). However, duration of treatment response varies, and most
patients eventually experience disease progression despite treatment. Leuprorelin is a
luteinizing hormone-releasing hormone (LHRH) agonist, a commonly used form of ADT.
Prostate-specific antigen (PSA) is a biomarker for monitoring disease progression and pre-
dicting treatment response and survival in PCa. However, time-dependent profile of tumor
regression and growth in patients with hormone-sensitive PCa on ADT has never been fully
characterized. In this analysis, nationwide medical claims database provided by Humana
from 2007 to 2011 was used to construct a population-based disease progression model for
patients with hormone-sensitive PCa on leuprorelin. Data were analyzed by nonlinear mixed
effects modeling utilizing Monte Carlo Parametric Expectation Maximization (MCPEM)
method in NONMEM. Covariate selection was performed using a modified Wald’s approxi-
mation method with backward elimination (WAM-BE) proposed by our group. 1113 PSA
observations from 264 subjects with malignant PCa were used for model development. PSA
kinetics were well described by the final covariate model. Model parameters were well esti-
mated, but large between-patient variability was observed. Hemoglobin significantly
affected proportion of drug-resistant cells in the original tumor, while baseline PSA and anti-
androgen use significantly affected treatment effect on drug-sensitive PCa cells (Ds). Popu-
lation estimate of Ds was 3.78 x 10−2 day-1. Population estimates of growth rates for drug-
sensitive (Gs) and drug-resistant PCa cells (GR) were 1.96 x 10−3 and 6.54 x 10−4 day-1, cor-
responding to a PSA doubling time of 354 and 1060 days, respectively. Proportion of the
original PCa cells inherently resistant to treatment was estimated to be 1.94%. Application
of population-based disease progression model to clinical data allowed characterization of
tumor resistant patterns and growth/regression rates that enhances our understanding of
how PCa responds to ADT.
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Introduction
Prostate cancer (PCa) is one of the most common cancers among men in the United States,
accounting for 44% of all cancer cases along with lung and bronchus, and colorectal cancers
[1]. In 2016, there were approximately 180,890 new cases of PCa and 26,120 deaths due to PCa
in the United States [1]. Clinically localized PCa is most commonly managed by observation,
radical prostatectomy, and radiotherapy (with or without androgen deprivation therapy, or
ADT) [2]. However, many patients diagnosed with localized disease ultimately undergo bio-
chemical progression as demonstrated by increasing levels in prostate-specific antigen (PSA),
who may then be treated by ADT. ADT acts by depleting gonadal testosterone [3], and it can
be achieved by medical castration through the use of luteinizing hormone-releasing hormone
(LHRH) agonists or antagonists, or surgical castration (bilateral orchiectomy), both of which
are considered equally effective. On the other hand, for patients who present with metastatic
PCa, ADT is considered the gold standard of initial therapy that has been shown to reduce
tumor-related events [4, 5]. ADT is a widely used systemic treatment for patients with hor-
mone-sensitive PCa, including those who previously receive local therapy as the primary treat-
ment modality and those who present with de novo metastatic disease. However, the majority
of patients eventually progress to a castration-resistant state, and it was estimated that the
response to ADT typically lasts 14 to 20 months in metastatic PCa [5, 6], and the duration of
response to ADT is variable among patients [7]. A few studies have examined clinical factors
that predict the time to castration resistance for patients on ADT [8–12], but the detailed time-
dependent profile of tumor regression and/or growth in patients with hormone-sensitive PCa
on medical ADT has never been fully characterized.
Quantitative population-based disease progression modeling uses mathematical functions
and statistical models to describe quantitatively the time course of disease progression in indi-
viduals and the entire patient population with or without drug treatment [13, 14]. This model-
ing approach can trace disease progression over time, and quantify the effects of drug
treatment and disease- and patient-specific factors on disease progression to optimize clinical
trial design and guide personalized treatment strategies [13]. For example, quantitative disease
progression modeling has been applied to clinical data to allow estimation of tumor growth
and regression rates in metastatic castration-resistant PCa [14]. Most of the published quanti-
tative population-based disease progression models are developed using data from random-
ized controlled studies [13–15]. While randomized controlled trials are the golden standard
for evaluating new drug treatment and the primary source of clinical research information,
they are costly, labor-intensive and time-consuming [16]. In addition, strict inclusion and
exclusion criteria are typically used to select subjects in randomized clinical trials within a pre-
defined study period, and thus the study results may have limited utility in answering clinical
questions in a real-life population [16, 17]. These limitations of randomized controlled trials
have led to an increased reliance on using medical claims data in designing healthcare policies
related to real-life clinical practice [16, 17]. Medical claims data are a rich and inexpensive
source of scientific information to study how a disease responds to medical interventions of
interest, and can provide an opportunity to potentially follow a large number of patients for
extended periods of time without suffering from high attrition rates [16–18]. To our knowl-
edge, medical claims data have never been used to develop quantitative population-based dis-
ease progression models, in which effects of drug treatment and patient-specific factors on
disease progression are evaluated and quantified.
The primary goal of this study was to use a medical claims database to construct a quantita-
tive population-based disease progression model for patients with hormone-sensitive PCa on
ADT with LHRH agonists. Leuprorelin, the most commonly prescribed LHRH agonist in the
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Medicare population [19], was selected as the treatment agent of interest in this analysis. Pros-
tate specific antigen (PSA) is an androgen-regulated serine protease produced almost exclu-
sively by cells in the prostate gland [20, 21]. PSA is commonly assessed for PCa screening, and
it remains an important marker for monitoring clinical response to ADT treatment [21–24].
Therefore, PSA was used as a molecular marker of tumor burden to measure disease progres-
sion of PCa in this study.
Materials and methods
Data source
This study was conducted in commercially insured patients using health claims data provided
by Humana covering the period from January 1, 2007 to December 31, 2011. This nationwide
database captures anonymized longitudinal, individual-level data on patient demographics,
healthcare utilization, inpatient and outpatient diagnostic and procedural codes, laboratory
test results, and pharmacy dispensing records for more than 8.1 million commercially insured
people in the United States. This study was approved by the Institutional Review Board at the
University of Kentucky, and the requirement to document informed consent was waived. All
data used in this study were anonymized and deidentified. Data retrieved from SQL queries
were pre-processed in R software (version 3.4.3, The R Foundation for Statistical Computing,
Austria) for dataset merging, wrangling and formatting (packages used: ‘readr’, ‘dplyr’,
‘stringr’, ‘ggplot2’, ‘data.table’).
Study subjects
Subjects were selected based on the following criteria: 1) diagnosis with malignant PCa (ICD-
9-CM code 185 or ICD-10-CM code C61), 2) continuous or intermittent use of leuprorelin as
the only agent among LHRH agonists, and 3) availability of a PSA level before initiation of leu-
prorelin (i.e, a baseline PSA level) and at least one level during treatment.
The following patients were excluded due to inability of our disease progression model to
describe certain unusual PSA profiles: 1) PSA levels decreased over time prior to initiation of
leuprorelin treatment, the baseline PSA level was undetectable, or there were multiple mea-
surements reported on the same day; 2) subjects had undetectable PSA levels throughout leu-
prorelin treatment. Patients were also excluded if 3) they had incomplete demographic data
(age, region and race). Lastly, patients were excluded if 4) they had extremely low hemoglobin
levels (< 6 g/dL), as acute illness was likely involved (S1 Fig).
For all selected subjects, PSA levels starting from baseline to the last available measurement
or before the initiation of continuous antiandrogen therapy, surgery, radiotherapy or chemo-
therapy (whichever occurred first) were included for model development. For each subject,
race, age, region and the use of antiandrogens (bicalutamide, enzalutamide, flutamide, niluta-
mide) within 30 days of leuprorelin initiation (presumably for preventing flare reactions asso-
ciated with leuprorelin treatment [6]) were extracted for model development. In addition,
laboratory measurements including those that have been reported to affect clinical outcomes
in castration-resistant PCa were extracted for each patient. These laboratory measurements
included aspartate transaminase (AST), alanine transaminase (ALT), serum creatinine (SCR),
alkaline phosphatase (ALP), albumin (ALB) and hemoglobin (HGB) [8, 9, 25–33].
Structural model
All modeling steps were conducted in NONMEM (ver. 7.3, ICON Development Solutions,
USA). Two mathematical models with different resistance development patterns were
PLOS ONE Disease progression modeling of hormone-sensitive prostate cancer
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developed to describe the observed PSA kinetics. In the first model (Model I), drug resistance
was developed from PCa tumor cells that were initially sensitive to LHRH treatment and
caused by adaptive responses, such as target gene mutations, altered expression of therapeutic
targets, and stimulation of compensatory signaling pathways [34]. The following equation
modified from Wilkerson et al [14] was used to describe Model I:
PSAt ¼ BAS � e
G�tsðe  D�tk þ eG�tk   1Þ ð1Þ
where PSAt is the tumor burden represented by the PSA level at time t (in days); BAS is the
baseline PSA; D is the drug effect on PSA, which decays over time due to the development of
drug resistance; and G is the rate of growth of PSA due to proliferating tumor. Ts represents
the time of PSA growth before the initiation of LHRH treatment; ts = t if t� time of the first
LHRH dose (t1) and ts = t1 if t>t1. Tk represents the time after the initiation of LHRH treat-
ment; tk = 0 if tk�t1 and tk = t-t1 if t>t1.
It is widely recognized that tumor is highly heterogeneous, thus drug resistance can occur
from treatment-induced selection of a subpopulation of drug-resistant cancer cells that existed
in the original tumor [34, 35]. Therefore, Model II in Eqs 2 and 3 was used to describe this
type of drug resistance:
PSARt ¼ BAS � ðRÞ � e
GR�t ð2Þ
PSASt ¼ BAS � ð1   RÞ � e
GS�ts � e  DS�tk ð3Þ
where PSART and PSAST represent PSA levels at time t produced by drug-resistant and drug-
sensitive cancer cell population, respectively. R is the proportion of drug-resistant cancer cells
in the initial tumor population. R is expressed as e-RP in the modeling process in order to
obtain values of R between 0 and 1. GR and GS are growth rates of PSA due to replicating drug-
resistant and drug-sensitive cancer cells, respectively. DS is the drug effect on PSA levels due to
killing of the drug-sensitive cancer cells. Ts represents the time of PSA growth before the initia-
tion of LHRH treatment; ts = t if t� t1 and ts = t1 if t>t1. Tk represents the time after the initia-
tion of LHRH treatment; tk = 0 if tk�t1 and tk = t-t1 if t>t1.
Inter-individual variability in the studied population was modeled for all parameters as fol-
lows:
yi ¼ yTypicale
Zi ð4Þ
where θi is a model parameter, θTypical is the typical value of the corresponding parameter in
the population, and ηi is a normally distributed random effect with a mean of 0 and a variance
of ωi2. The residual error model in the analysis was additive error as follows:
DVij ¼ dDVij þ �ij ð5Þ
where DVij and dDVij stand for jth log observed and predicted concentration for the ith subject.
εij follows normal distribution with a mean of 0 and a variance of s2add. Proportional error
model and mixed error model were also assessed in the analysis.
Data were analyzed by nonlinear mixed effects modeling utilizing the Monte Carlo
Parametric Expectation Maximization (MCPEM) method in NONMEM software (version 7.3,
ICON Development). The details of the MCPEM algorithm have been presented elsewhere
[36–38]. Briefly, two-stage hierarchical nonlinear mixed effects modeling was used to find the
optimal population mean μ and variance O that best describe the observed data. Final popula-
tion parameters μ and O were obtained by first evaluating the conditional mean �yiand
PLOS ONE Disease progression modeling of hormone-sensitive prostate cancer
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conditional variance �Bi for each subject using fixed values of μ and O (the expectation step E)
according to Eqs 6 and 7, followed by evaluating updates to μ and O using Eqs 8 and 9 (the
maximization step M) [37–39].
Expectation (E) step:
�yi
¼
PN
k¼1 ykWðliðykÞ; hðykÞÞ
PN
k¼1 WðliðykÞ; hðykÞÞ
ð6Þ
�Bi¼
PN
i¼1ðyk  
�yi
Þðyk  
�yi
Þ
0
WðliðykÞ; hðykÞÞ
PN
i¼1 WðliðykÞ; hðykÞÞ
ð7Þ
Maximization (M) step:
m ¼
1
m
Pm
i¼1
�yi
ð8Þ
m ¼
1
m
Pm
i¼1ð
�yi
  mÞð�yi
  mÞ
0
þ
1
m
Pm
i¼1
�Bi ð9Þ
where li(θk) is the likelihood function for subject i regarding to parameter θk given data; h(θk)
is the density function of θk given μ and O. The weight W depends on likelihood function,
li(θk), density function (suppressing dependence on μ and O), and the method of Monte-Carlo
method used, for N randomly generated parameter vectors of θk. m represents the total num-
ber of subjects in the analysis. E and M steps were repeated until μ and O no longer change
[36, 37]. At this point, final population parameters μ and O that best described the data were
obtained. In MCPEM, the Monte-Carlo integration method was used to evaluate �yiand
�Bidur-
ing the expectation step [36, 37].
The parameters of the developed models were obtained by fitting the models to PSA levels
from all subjects simultaneously. Comparison of alternative nested structural models was
based on the typical goodness-of-fit diagnostic plots and likelihood ratio test [40, 41]. When
comparing alternative nested hierarchical models, the differences in objective function value
(OFV), defined as -2log(likelihood), are approximately chi-square distributed with n degrees of
freedom (n is the difference in the number of parameters between the full and the reduced
model) [41]. Differences in OFV of greater than 10.83 for one degree of freedom, correspond-
ing to a significance level of 0.001, were used to discriminate two nested hierarchical models.
This stringent criterion was used because of multiple comparisons inherent in the model selec-
tion procedure and random noise associated with the Monte-Carlo sampling technique
employed in the MCPEM algorithm [39, 40, 42]. The number of simulated Monte-Carlo
parameter sets (ISAMPLE) used for the E step evaluation determined the random noise associ-
ated with model parameters and likelihood estimation in the MCPEM method. Larger ISAM-
PLE was associated with lower random noise of likelihood for more reliable model selection
but at the expense of increased computation times. Therefore, to achieve the desirable balance
between random noise of model parameters/likelihood and computation time, a sequential
approach with different ISAMPLE in different stages of the MCPEM was used in the analysis.
First, ISAMPLE of 1000 for first 150 EM iterations and then ISAMPLE of 2000 for another 50
EM iterations were used in the burn-in phase of MCPEM to achieve the stationary phase rap-
idly. Then, ISAMPLE of 50,000 for 50 EM iterations was used to obtain stable and desirable
final model parameter estimates using MCPEM model convergence criteria described previ-
ously [42]. In brief, last five EM iterations of population mean parameters and inter-subject
PLOS ONE Disease progression modeling of hormone-sensitive prostate cancer
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variances with ISAMPLE of 50,000 at stationary state were examined using linear regression
analysis. A Bonferroni method using the following equation was used to adjust the p value of
linear regression analysis for multiple hypothesis testing:
aB ¼
a
B
ð10Þ
where αB, α, and B were the Bonferroni-adjusted p value, preset p value (set at 0.05), and the
number of tested parameters, respectively. If changes in all tested parameters across iterations
were not statistically different from zero, then model convergence is assumed. To compare
non-nested models such as Models I and II in this study, the following Akaike information cri-
terion (AIC) was used to select the best model with lowest AIC value:
AIC ¼ OFV þ 2 � NPAR ð11Þ
where NPAR is the total number of model parameters.
PSA concentrations below 0.1 ng/ml (lower limit of assay quantification) were treated as
fixed point censored observations, and the maximum likelihood was used to fit the model to
the censored observations [42, 43]. In this case, the likelihood for all data is maximized with
respect to model parameters, and the likelihood for a censored concentration was taken to be
the likelihood that the censored observation is truly below the limit of quantification. This
approach allowed PSA levels <0.1 ng/mL to be included into model development to better
characterize the PSA kinetics and treatment effect of leuprorelin.
Covariate analysis
In order to investigate and quantify relationships between important model parameters and
patient-specific factors (covariates), final covariate model was developed using a modified
Wald’s approximation method with backward elimination (WAM-BE) proposed by our group
[44, 45]. In brief, all potential covariate-parameter relationships were incorporated into the
best structural model to form the full model with covariates. Parameter estimates and the
covariance matrix (COV) from the full model fit were used to calculate the Wald’s approxima-
tion statistics. Assuming the vector of fixed-effect covariate parameters was k×1 vector θ, and
the corresponding COV for these parameters was k×k matrix C. θ could be partitioned to p×1
vector θ1 and q×1 vector θ2, where θ1 were fixed-effect covariate parameters that need to be
estimated and θ2 were covariate parameters restricted to zeros under the hypothesized submo-
del. Then θ and the corresponding C could be defined as follows:
θ ¼
θ1
θ2
 !
and C ¼
C11 C12
C21 C22
 !
ð12Þ
The Wald’s approximation to the likelihood ratio test (LRT) statistic (Λ´) for the hypothe-
sized submodel that θ2 = 0 was described by the equation:
L
0
¼ θ0
2
C  1
22
θ2 ð13Þ
It has been shown that maximum likelihood estimates of θ followed asymptotically multi-
variate normal distribution with covariance matrix C [46]. Under H0: θ2 = 0, the asymptotical
distribution of Λ´ followed w2q distribution, and hypothesis testing could be applied to decide
whether or not to reject H0. The calculation of Λ´ in Eq 13 did not require running the submo-
dels, and therefore, multiple hypotheses could be efficiently tested by using results from the
full model fit. In WAM-BE method, the backward elimination (BE) process was used to screen
PLOS ONE Disease progression modeling of hormone-sensitive prostate cancer
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and eliminate insignificant covariates from the full model based on the difference in values of
Λ´between two models. Differences in Λ´ of greater than 10.83 for 1 degree of freedom, corre-
sponding to a significance level of 0.001, were used to discriminate two nested hierarchical
models. The best models selected by BE approach based on Λ´ values were then used as the
starting models for selecting the final covariate model using actual NONMEM runs with the
BE process.
Continuous covariates were added into the structural model as follows [40]:
yi ¼ yTypical
COVj
medianðCOVjÞ
 !ycovij
ð14Þ
where COVj is the value of jth continuous covariate, and θcovij is the effect the jth covariate has
on the ith parameter.
Categorical covariates were added as follows:
yi ¼ yTypical � e
ðCOVj�ycovijÞ ð15Þ
where COVj is an indicator variable (e.g., if the categorical variable is gender, COVj = 1 when
the subject is male, and COVj = 0 when the subject is female).
The final model was evaluated by routine diagnostic plots. Additionally, prediction-cor-
rected visual predicted check (VPC) was done in PsN (ver. 4.9.0, Uppsala University, Sweden)
using 1000 simulations and automatic binning, to assess the performance of the final model
[47]. The final population model was used to examine the effects of statistically significant
covariates on clinical outcomes associated with leuprorelin treatment. PSA progression is
defined by the Prostate Cancer Clinical Trials Working Group (PCWG2 and PCWG3) as “the
date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the
nadir is documented, which is confirmed by a second value obtained 3 or more weeks later”
[48, 49]. The percentages of leuprorelin-treated subjects with PSA progression within one,
two, and three years simulated from 1000 subjects using 5th percentile, median and 95th per-
centile values of continuous covariates and different categories of categorical variables were
obtained and compared. Simulation was conducted with the final population model using R.
The parallel computing platform of NONMEM was implemented in a single workstation
equipped with dual Intel Xeon E5-2698 v4 20-cores CPU with 2.20 GHz, a Windows 10 Enter-
prise operating system and Intel Parallel Studio XE 2016 Fortran compiler.
Results
A total of 1113 PSA observations from 264 subjects were used for model development. Baseline
demographic data and laboratory values of all subjects are summarized in Table 1. The study
population had a median age of 80 and median baseline PSA of 8.5 ng/mL. There was no miss-
ing baseline demographic data and laboratory values among subjects included in the analysis.
Model I that assumed drug resistance was developed from PSA-producing PCa cells that
were initially sensitive to LHRH treatment, had an AIC value of 865.432. Model II that
assumed drug resistance was originated from treatment-induced selection of a subpopulation
of drug-resistant PSA-producing cancer cells, had a lower AIC of 295.671. Therefore, Model II
was selected as the structural model. Use of proportional or mixed error models resulted in
unstable models, so an additive error model was used. HGB was a significant covariate that
affects the proportion of drug-resistant cells (R or e-RP) in the original tumor. Baseline PSA
(BAS) and antiandrogen use (AND) were significant covariates on the drug killing effect of
drug-sensitive PSA-producing cancer cell population (DS). Addition of these three covariates
PLOS ONE Disease progression modeling of hormone-sensitive prostate cancer
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into the model resulted in significant decrease in OFV (50.008; p<0.001 for degrees of free-
dom = 3). The final model with covariates was presented as follows:
RP ¼ yRP
HGB
13:6
� �yHGB RP
ð16Þ
DS ¼ yDS �
BAS
8:5
� �yBAS DS
� eINDAND�yAND DS ð17Þ
where θHGB_RP and θBAS_DS are model parameters used to describe the effect of HGB on RP
and BAS on DS, respectively. θAND_DS is used to describe the effect of AND on DS. INDAND = 1
if the patient used antiandrogen within 30 days of leuprorelin initiation and = 0 otherwise. The
parameter estimates of the final model with covariates are presented in Table 2. All model
parameters were estimated with good precision (percent coefficient of variation, %CV<50).
The population estimate of DS was 3.78 x 10−2 day-1. Population estimate of growth rate for
drug-sensitive PSA-producing tumor cell population (GS) was 1.96 x 10−3 day-1, corresponding
to a PSA doubling time of 354 days. Population estimate of RP was 3.94, indicating that 1.94%
Table 1. Summary of baseline demographic data and laboratory values of subjects included in model
development.
Baseline characteristics Median (range) or counts
Age (years) 80 (60–100)
Race
Caucasian 189
Black 59
Hispanic/other 16
Region
South 196
West 20
Midwest 42
Northeast 6
Antiandrogen use
Yes 33
No 231
aAST (IU/L) 20 (9–91)
bALT (IU/L) 18 (4–110)
cSCR (mg/dL) 1.10 (0.700–9.30)
dALP (IU/L) 76.5 (23.0–3640)
eALB (g/dL) 4.13 (2.90–4.80)
fHGB (g/dL) 13.6 (6.80–17.4)
Baseline gPSA (ng/mL) 8.50 (0.200–782)
Data are presented as median (range) or counts.
aaspartate transaminase
balanine transaminase
cserum creatinine
dalkaline phosphatase
ealbumin
fhemoglobin
gprostate-specific antigen.
https://doi.org/10.1371/journal.pone.0230571.t001
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(calculated from R = e-RP) of the original PSA-producing cancer cell population was inherently
resistant to leuprorelin treatment. Population estimate of growth rate for drug-resistant PSA-
producing cancer cell population (GR) was 6.54 x 10−4 day-1, corresponding to a PSA doubling
time of 1060 days.
Large between-patient variability was observed in these parameters, possibly due to diverse
PSA kinetics in the studied population. The estimated value of θHGB_RP was 2.30, suggesting
that subjects with lower HGB levels had lower RP and therefore were less likely to respond to
leuprorelin treatment. Typical values of RP were 2.37, 3.94, and 5.73 for subjects with 5th per-
centile (10.9 g/dL), median (13.6 g/dL), and 95th percentile (16.0 g/dL) levels of HGB, respec-
tively. The corresponding proportions of resistant PSA-producing cancer cell population in
the original tumor were 9.36%, 1.94%, and 0.326%, respectively. The estimated value of
θBAS_DS was 0.174, indicating that higher baseline PSA levels were associated with better
LHRH-treatment effect on PSA level due to killing of drug-sensitive cancer cell population.
Typical values of DS were 2.32 x 10−2, 3.78 x 10−2, and 5.99 x 10−2 day-1 for subjects with 5th
percentile (0.515 ng/mL), median (8.50 ng/mL), and 95th percentile (120 ng/mL) levels of BAS,
respectively. The estimated value of θAND_DS was 6.77 x 10−1, implying that subjects with anti-
androgen use within 30 days of leuprorelin initiation was associated with 96.8% higher LHRH
treatment effect on killing of drug-sensitive PSA-producing cancer cell population compared
to those without antiandrogen use.
As shown in Fig 1, diverse PSA kinetics profiles from different patients were well described
by the final model. The diagnostic plots in Fig 2 and the prediction-corrected VPC plot shown
Table 2. Parameter estimates of the final PSA kinetics model.
Parameter Estimate a%CV
Structural Model
bDS (day-1) 3.78 x 10−2 6.19
cGs (day-1) 1.96 x 10−3 22.5
dRP 3.94 7.44
eGR (day-1) 6.54 x 10−4 28.4
Interindividual Variability
o2DS 0.453 14.8
o2GS 2.59 19.7
o2RP 0.944 16.4
o2DR 3.76 21.1
Covariate Model
fHGB on RP (θHGB_RP) 2.30 24.7
gBAS on DS (θBAS_DS) 0.174 24.5
hAND on DS (θAND_DS) 0.677 30.0
Residual Variability
Additive error (σadd) 2.01x10-1 3.49
a%CV = percent coefficient of variation
bdrug effect on drug-sensitive tumor cells
cgrowth rate of drug-sensitive cells
dexp(-RP) represents the fraction of drug-resistant tumor cells in the original tumor
egrowth rate of drug-resistant cells
feffect of hemoglobin level on RP
geffect of baseline prostate-specific antigen level on Ds
heffect of antiandrogen use on Ds
https://doi.org/10.1371/journal.pone.0230571.t002
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in S2 Fig show that the observed PSA values were generally in agreement with predicted PSA
levels, and that the final model provided a good fit for the data. The final model was then used
in simulation to assess effects of HGB, BAS and AND on PSA progression within one, two and
three years, and the results are shown in Fig 3. The percentages of leuprorelin-treated subjects
with PSA progression within one year for subjects with 5th percentile, median and 95th percen-
tile of HGB were 19.8, 13.9 and 10.5, respectively (Fig 3A). 38.8, 28.2, and 22.1% of the leupror-
elin-treated subjects with 5th percentile, median and 95th percentile of HGB were expected to
experience PSA progression within three years after initiation of leuprorelin treatment. The
percentages of leuprorelin-treated subjects with PSA progression within one year in subjects
with 5th percentile, median and 95th percentile of BAS were 6.9, 13.9, and 25.6, respectively
(Fig 3B). The percentages of leuprorelin-treated subjects with PSA progression within three
years in subjects with 5th percentile, median and 95th percentile of BAS were 15.8, 28.2, and
47.8, respectively (Fig 3B). 28.5% of leuprorelin-treated subjects with antiandrogen use and
28.2% of those without antiandrogen use were expected to experience PSA progression within
three years of treatment period.
Discussion
To the best of our knowledge, this was the first study to use medical claims data to construct a
population-based disease progression model to describe PSA kinetics in patients with hor-
mone-sensitive PCa treated with leuprorelin. Furthermore, the model could quantify effects of
patient-specific factors (covariates) on model parameters and PSA kinetics in these patients.
Although leuprorelin was selected as the only form of ADT in this analysis, we would expect
that our results could be extrapolated to other LHRH agonists, given the similarity in their effi-
cacy reported in clinical trials [50, 51].
Population data analysis using nonlinear mixed effects modeling approach has been shown
to provide precise and robust estimates of drug-related model parameters and their population
variability using clinical data [41, 52]. Among different nonlinear mixed effects modeling
methods, MCPEM was used to successfully develop the final population disease progression
model in this study, due to the ability of this method to precisely approximate the true log-like-
lihood, and its stability and amenability to efficient parallel computing when dealing with
complex models with large datasets [38, 39, 53].
One of the important goals in population-based disease progression modeling is to quantify
effects of covariates on model parameters and clinical outcomes. Established quantitative rela-
tionships are useful for helping clinicians make conscious decisions on selecting optimal drug
treatment, with the ultimate goal of implementing individualized or personalized medicine
[54]. However, development of population-based disease progression models with covariate-
parameter relationships is both time-consuming and labor-intensive, as many submodels with
different covariate-parameter relationships need to be created, tested, and compared. There is
a total of 24x11 = 1.76 x 1013 possible submodels with different covariate-parameter relation-
ships in this study. Due to the structural model complexity and large number of observations,
a single covariate model run with ISAMPLE of 50,000 executed in parallel mode with 25 Intel
Xeon 2.2 GHz E5-2968 v4 computing cores took about 10 min to complete. Therefore, it was
impossible to explore all the possible submodels in this setting. Hence, the WAM-BE method
originated by our group was used to develop covariate models [45]. WAM-BE only requires a
single full model fit and does not require fitting the submodels to estimate the difference in
OFV between two tested models for covariate selection. In addition, WAM-BE is designed to
overcome the inherent limitation of the original WAM method in population data analysis
[44] and it achieved comparable results with significantly shorter computational time in
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models with large numbers of model parameters and tested covariates. Although the original
WAM method uses the Wald approximation to LRT statistic (Λ´) from the full model instead
of actual NONMEM model runs to screen covariate models, it is extremely inefficient in the
presence of large numbers of tested model parameters and covariates due to the need to calcu-
late Λ´ values for all possible covariate models. In this study, 1.76 x 1013 possible covariate
models needed to be screened and tested with the original WAM method. Assuming the time
to compute Λ´ value for a covariate model was about 10−6 seconds, a total of 1.76 x 107 seconds
or 203 days would be needed to calculate Λ´ values of all possible covariate models. To over-
come this limitation, we used the sequential backward elimination (BE) process to efficiently
eliminate any insignificant covariate models to generate the best starting models, which were
subject to subsequent actual NONMEM runs with the BE process to select the final covariate
model. Therefore, the WAM-BE method significantly reduced the number of covariate models
needed to be tested using WAM-derived Λ´ values and actual NONMEM runs, and it only
took about 39 min for our workstation to develop the final covariate model.
ADT is the standard of care for patients with hormone-sensitive PCa, but most patients
develop castration resistance within 1–3 years [53]. The underlying mechanism is thought to
be multifactorial and involve several molecular and genetic alterations, and the “adaptation”
and the “clonal selection” models have been proposed to explain this phenomenon [55]. With
the “adaptation” model, early PCa cells are assumed to have similar androgen requirement for
survival and growth, and castration resistance stems from genetic or epigenetic alterations in
the cells. With the “clonal selection” model, it is assumed that early PCa cells have heteroge-
neous androgen requirement, and after ADT castration-resistant cells gradually outgrow cas-
tration-sensitive cells due to the survival advantage of the former [56].
In our model, PSA was used as a marker of tumor burden in the modeling of disease pro-
gression, as PSA levels are routinely used for disease monitoring and surveillance purposes in
PCa [20–23], and they are readily retrievable from health claims database. PSA level has been
shown to be closely related to the tumor volume [57], and it was found to reflect the androgen
milieu in patients with localized PCa on ADT [51]. A rising PSA is usually the first sign of
tumor regrowth, followed by worsening of disease identified by imaging and development of
clinical symptoms [49]. In this study, Model I was the mathematical representation of “adapta-
tion” model that assumed drug resistance was developed from PSA-producing cancer cells ini-
tially sensitive to LHRH treatment. On the other hand, Model II was the “clonal selection”
model that assumed drug resistance was developed from a subpopulation of drug-resistant
PSA-producing cancer cells in the original tumor. Our predefined model selection criteria
determined that Model II was superior than Model I at describing the PSA profiles of our
study subjects, and this finding was consistent with the observations from some recent studies
[55].
Based on recent recommendations from the PCWG, PSA responses to drug treatment that
affect tumor cell kill can be categorized into three distinct patterns: 1) significant and sustained
PSA decline after drug treatment for “responders”, 2) initial decline followed by a slow PSA
increase for “partial responders”, and 3) a transient decrease followed by a rapid PSA increase
observed in “non-responders” [49]. As shown in Fig 1, the final model in this study was able to
adequately describe these three distinct PSA responses to leuprorelin treatment. Furthermore,
the model was able to provide additional biological insight into the observed PSA patterns. For
example, Subject C in Fig 1C showed least response to treatment and most significant increase
in PSA within the follow-up period among the representative subjects. The modeling results
suggested that this subject had a high percentage of drug-resistant cancer cell population of
28.1% and high growth rate of the resistant tumor cell population of 7.97 x 10−3 day-1, both of
which were more than 10 times higher than the population mean values. On the other hand,
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Fig 1. Profiles of PSA kinetics in representative patients with hormone-sensitive prostate cancer. Black line represents model-predicted PSA
levels. Open circles and solid circles represent observed PSA levels above the lower limit of quantification (LLOQ) and observed PSA levels below
the LLOQ, respectively. Red and green vertical dashed lines represent the first and the last recorded date of leuprorelin treatment, respectively.
Blue horizontal dotted line represents the LLOQ value of the PSA assay. Black arrows represent the fill dates of leuprolide.
https://doi.org/10.1371/journal.pone.0230571.g001
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the profile of Subject B in Fig 1B was characterized by a decrease followed by a slow increase of
PSA. As shown in Fig 4B, the rapid but transient decline in the total PSA level after leuprorelin
treatment was due to the killing of drug-sensitive PSA-producing cancer cell population. How-
ever, the high growth rate of drug-resistant PSA-producing cancer cell population of 1.53 x
10−2 day-1 (compared to the population estimate of 6.54 x 10−4 day-1) contributed to the subse-
quent steady rise in PSA level observed in this subject. On the other hand, PSA profile of Sub-
ject A in Fig 1A was characterized by significant and sustained PSA decline after leuprorelin
treatment and therefore could be described as a "responder”. The low percentage of drug-
Fig 2. Diagnostic plots for the final disease progression model. From left to right and top to bottom: Observed log PSA concentrations (DV)
versus individual log predicted values (IPRED), individual weighted residuals (IWRES) versus the IPRED, IWRES versus time, and expected
conditional weighted residuals (ECWRES) versus the expected log predicted values (EPRED). The red line represents the loess regression line.
https://doi.org/10.1371/journal.pone.0230571.g002
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resistant PSA-producing cancer cell population of 6.36 x 10−2% combined with the slow
growth rate of the drug-resistant PSA-producing cancer cell population of 3.53 x 10−4 day-1
contributed to the sustained PSA decline in this subject (Fig 4A).
Only a few studies have attempted to develop predictor models for development of castra-
tion resistance in patients with hormone-sensitive PCa. Most of these predictive models were
developed using multivariate analysis that provides very little biological insight on the relation-
ship between identified predictors and disease progression [8–12]. Several PSA kinetic param-
eters such as time to PSA nadir and PSA nadir level have been shown to be significant
predictors of disease progression for PCa patients receiving ADT [9–11]. However, the com-
plex quantitative relationship between clinical predictors and PSA kinetics and disease pro-
gression in ADT-treated PCa patients remains largely unknown. In this study, we developed
the first mechanistic population-based disease progression model that allowed us to investigate
such complex relationship. Baseline PSA and HGB were identified as important covariates on
PSA kinetics, consistent with previous findings that these two covariates played an important
role in the development of castration resistance [8, 9, 12]. However, these two covariates
affected different model parameters and hence had very different results on PSA kinetics and
biochemical progression. Both baseline PSA and antiandrogen use were statistically significant
covariates on drug-killing effect on leuprorelin-sensitive PSA-producing cancer cells, and
HGB significantly affected the fraction of cancer cells resistant to leuprorelin treatment. Drug-
killing rates on leuprorelin-sensitive PSA-producing cancer cells were higher in subjects with
higher baseline PSA levels and those with antiandrogen use within the 30 days of leuprorelin
treatment initiation, compared to those with lower baseline PSA levels and those without anti-
androgen use. Subjects with lower hemoglobin levels had higher fraction of leuprorelin-resis-
tant cancer cells in the original tumor.
Subsequently, simulation was performed to evaluate the relationship between these covari-
ates and PSA kinetics and disease progression. The results showed that subjects with higher
baseline PSA levels were more likely to experience PSA progression (Fig 3B), which may seem
counterintuitive given that higher baseline PSA was associated with higher drug-killing effect
on leuprorelin-sensitive PSA-producing cancer cells in our model. Further analysis of the sim-
ulated results showed that the baseline PSA level had a complicated effect on the overall PSA
kinetics. The simulated median time to nadir levels was 294, 198, and 135 days after initiation
of leuprorelin in subjects with 5th percentile (0.515 ng/mL), median (8.50 ng/mL) and 95th per-
centile (120 ng/mL) of baseline PSA levels, respectively. The simulated median nadir levels
were 0.0220, 0.290, and 3.47 ng/mL for leuprorelin-treated subjects with 5th percentile, median
and 95th percentile of baseline PSA levels, respectively. Therefore, subjects with higher baseline
PSA levels had higher velocity of PSA decline and shorter time to achieve the nadir level after
treatment initiation, which was consistent with higher drug-killing effect on leuprorelin-sensi-
tive cancer cells in these subjects. Furthermore, subjects with higher baseline PSA levels also
had higher nadir PSA levels, possibly due to presence of higher numbers of leuprorelin-resis-
tant cancer cells, and therefore they were more likely to experience PSA progression. Overall,
our results confirmed findings from previous studies that associated higher baseline PSA levels
with shorter time to castration resistance, and they were also in agreement with observations
from Ji et al that higher PSA nadir, higher velocity of PSA decline and shorter time to PSA
nadir were predictive of increased risk of progression to castration resistance [11]. On the
Fig 3. Simulation results for percentages of subjects with PSA progression within one, two, and three years. 3A
and 3B show simulated PSA progression in subjects with 5th percentile, median and 95th percentile of hemoglobin
level and baseline PSA level, respectively.
https://doi.org/10.1371/journal.pone.0230571.g003
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other hand, subjects with lower levels of HGB were shown to have a higher chance of PSA pro-
gression (Fig 3A), consistent with results from previous studies [8, 12]. Mechanistically, the
simulated median time to nadir levels were 155, 198, and 240 days after initiation of leuprore-
lin in subjects with 5th percentile (10.9 g/dL), median (13.6 g/dL) and 95th percentile (16.0 g/
dL) of HGB levels, respectively. The simulated median nadir levels were 1.19, 0.290, and
0.0574 ng/mL for subjects with 5th percentile, median and 95th percentile of HGB levels,
respectively. Again, we could see that subjects with lower HGB levels had higher PSA nadir,
higher velocity of PSA decline and shorter time to PSA nadir, which were the identified PSA
kinetic risk factors predictive of shorter time to biochemical progression. Lastly, while use of
antiandrogen within 30 days of initiation of leuprorelin treatment was identified as a statisti-
cally significant covariate affecting drug-killing effect on leuprorelin-sensitive PSA producing
tumor cells, it had minimum effect on PSA progression in our simulation. One plausible expla-
nation was that as antiandrogen use could only be temporary in the study population, the
observed inhibitory effect was most likely on PSA flare alone, which has not been found to be
associated with tumor progression and negative outcomes [58].
There are several limitations to our study. First, while medical claims database can be used
for longitudinal population studies to address questions in real-life clinical practice, the highly
heterogeneous nature of the database posed technical challenges to data analysis. For example,
patients on both continuous and intermittent regimens of leuprorelin were included in the
analysis, as it was difficult to quantitatively identify and separate these two types of treatment
regimens based on claims data alone. Additionally, because of the heterogeneity of dosing regi-
mens in the studied population, patient compliance could not be accurately assessed. Intermit-
tent ADT has been extensively tested in PCa patients since the 1980s, mainly due to evidence
of its anticancer efficacy and its ability to reduce ADT-related adverse effects [59]. With inter-
mittent ADT, the patient receives ADT for several months consecutively until PSA levels drop
below a predetermined threshold, after which the patient enters an off-treatment period [60].
Patients receiving the two treatment modalities may have different patterns of disease progres-
sion. Nevertheless, two randomized trials showed that intermittent ADT was noninferior to
continuous ADT in terms of survival endpoints in PCa patients [61, 62], while the largest trial
so far comparing continuous and intermittent ADT could not conclude or exclude noninfer-
iority of intermittent ADT [63]. In our preliminary analysis, dose intensity (leuprolide dose
received normalized to an expected dose of 7.5 mg per month) was calculated. As expected,
dose intensity varied greatly among patients on continuous and intermittent ADT, and it did
not have statistically significant effect on model parameters. Additionally, exclusion of a large
proportion of patients (86.4%) diagnosed with malignant PCa and treated by leuprorelin in
our effort to build an explainable model, as well as the presence of large between-patient vari-
ability observed in some model parameter estimates, may pose a limitation to interpretation of
our findings. Nevertheless, retrospective nature of this study suggested that our findings will
need to be validated in prospective clinical studies. Second, some clinical measures that assess
disease severity and/or metastasis spread, including metastasis stage, the Gleason score, East-
ern Cooperative Oncology Group (ECOG) performance status and the Soloway score, were
shown to be predictive of biomedical progression [9, 11, 12]. However, they were not available
in the medical claims database, and therefore they could not be evaluated for their importance
in our model. Similarly, though LHRH agonists have been assumed to cause testosterone sup-
pression [64], testosterone levels were not available in our patient database for us to investigate
the possibility of incomplete testosterone suppression and its potential relationship with PSA
kinetics. Third, as survival data were not available in our database, analyses linking PSA kinet-
ics and biomedical progression to survival endpoints were not conducted in this analysis. Last
but not least, though PSA level has been previously shown to be significantly associated with
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Fig 4. Simulated total PSA and PSA produced by drug-sensitive and drug-resistant tumor cells in representative
subjects. 4A and 4B demonstrate simulated PSA levels in a “responder” Subject A and a “partial responder” Subject B,
respectively. Black line represents model predicted total PSA level. Pink and grey solid lines represent model predicted
PSA from drug-sensitive and drug-resistant tumor cells, respectively. Red and green vertical dashed lines represent the
first and the last recorded date of leuprorelin treatment, respectively. Blue horizontal dotted line represents the lower
limit of quantification (LLOQ) of the PSA assay.
https://doi.org/10.1371/journal.pone.0230571.g004
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tumor volume [57], it is not as accurate as quantitative imaging biomarkers in representing the
tumor burden, and the PSA response does not always associate with treatment response or sur-
vival [65].
Conclusions
In summary, in this study a novel population-based modeling approach was used to provide
the first mechanistic insight on how PSA kinetics contributed to the subsequent development
of castration resistance in patients with hormone-sensitive PCa treated with leuprorelin. Com-
pared to previous studies, our study successfully modeled the underlying resistance mecha-
nism of PCa cells and provided new biological insight into PSA kinetics in this patient
population of interest. The application of population-based disease progression model to exist-
ing clinical data allowed estimation of tumor resistant patterns and growth/regression rates
that could greatly enhance our understanding of how hormone-sensitive PCa responds to
LHRH agonists. It may serve as a platform for incorporating more comprehensive health data
in the future, including laboratory measurements, genomic and proteomic data to further per-
sonalized medicine in patients with hormone-sensitive PCa.
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